Literature DB >> 10375558

IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men.

E Jouanguy1, R Döffinger, S Dupuis, A Pallier, F Altare, J L Casanova.   

Abstract

The development of gene-knockout mice and the identification of gene-deficient humans have improved our understanding of the role of IL-12 and IFN-gamma in host defense. Comparison of experimental and natural infections has shown that animals and humans genetically deficient in immunity mediated by IL-12 or IFN-gamma are highly susceptible to mycobacteria and salmonella. Impaired secretion of, or response to, IFN-gamma is the common pathogenic mechanism that accounts for impaired granuloma formation and uncontrolled growth of bacteria within macrophages. The axis formed between IL-12 and IFN-gamma is essential for protective immunity against mycobacteria and salmonella in mice and men.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375558     DOI: 10.1016/s0952-7915(99)80055-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  116 in total

1.  Formation of granulomas in the lungs of severe combined immunodeficient mice after infection with bacillus Calmette-Guerin.

Authors:  T Goldmann; G Zissel; R Sen Gupta; M Schlaak; E Vollmer; J Müller-Quernheim
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  CD4 T cells producing IFN-gamma in the lungs of mice challenged with mycobacteria express a CD27-negative phenotype.

Authors:  I V Lyadova; S Oberdorf; M A Kapina; A S Apt; S L Swain; P C Sayles
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

3.  NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8⁺ T cells.

Authors:  Andreas Kupz; Greta Guarda; Thomas Gebhardt; Leif E Sander; Kirsty R Short; Dimitri A Diavatopoulos; Odilia L C Wijburg; Hanwei Cao; Jason C Waithman; Weisan Chen; Daniel Fernandez-Ruiz; Paul G Whitney; William R Heath; Roy Curtiss; Jürg Tschopp; Richard A Strugnell; Sammy Bedoui
Journal:  Nat Immunol       Date:  2012-01-08       Impact factor: 25.606

Review 4.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

Review 5.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

6.  Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy.

Authors:  Suranjith Luke Seneviratne; Rainer Doffinger; John Macfarlane; L Ceron-Gutierrez; M R Amel Kashipaz; A Robbins; T Patel; P T Powell; D S Kumararatne; Richard J Powell
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

7.  Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol.

Authors:  Michael E Abrams; Kristen A Johnson; Sofya S Perelman; Li-Shu Zhang; Shreya Endapally; Katrina B Mar; Bonne M Thompson; Jeffrey G McDonald; John W Schoggins; Arun Radhakrishnan; Neal M Alto
Journal:  Nat Microbiol       Date:  2020-04-13       Impact factor: 17.745

Review 8.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

9.  Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response.

Authors:  M L V Watkins; P L Semple; B Abel; W A Hanekom; G Kaplan; S R Ress
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

10.  Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.

Authors:  Priscille Brodin; Karin Eiglmeier; Magali Marmiesse; Alain Billault; Thierry Garnier; Stefan Niemann; Stewart T Cole; Roland Brosch
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.